ecrin-mdr-crcClinical2019IPD Sharing (as of March 2023): No Description: No IPD will be sharedColorectal CancerColorectal NeoplasmsAdvanced metastatic colorectal cancerMetastatic colorectal cancerMetastatic Colorectal CancerAdvanced Metastatic Colorectal CancerColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2272605Germany1RamucirumabTas102ECRIN MDRActive, not recruitingfalseRAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer PatientsInterventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb study in patients with advanced metastatic colorectal cancer. The scope of the trial is to evaluate overall survival of either regimen (TAS102 +/- Ramucirumab) and evaluate safety and tolerability.2019-01-152272605NCT035209462017-004162-99